Relationship between the weight of parathyroid glands and their secretion of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism

Therapeutic Apheresis and Dialysis

Volumn 12, Issue 5, 2008, Pages 385-390

  Kakuta, Takatoshi ^a   Tanaka, Reika ^a   Kanai, Genta ^a   Miyamoto, Yoshiyasu ^a   Inagaki, Miho ^a   Suzuki, Hajime ^a   Fukagawa, Masafumi ^b   Saito, Akira ^b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hemodialysis patients; Parathyroid hormone (1 84); Parathyroid hyperplasia; Parathyroidectomy; Secondary hyperparathyroidism

Indexed keywords

PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; GLOMERULONEPHRITIS; HEMODIALYSIS; HORMONE RELEASE; HUMAN; KIDNEY FAILURE; MAINTENANCE THERAPY; MALE; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM;

ADULT; AGED; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; ORGAN SIZE; PARATHYROID GLANDS; PARATHYROID HORMONE; PARATHYROIDECTOMY; PREDICTIVE VALUE OF TESTS; PROBABILITY; RENAL DIALYSIS; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER;

EID: 53749088325     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2008.00614.x     Document Type: Article

References (26)

1. Drueke TB. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 1995 48 : 259 72.
2. US Renal Data System. USRDS 2000 Annual Report. Bethesda : National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases, 2000.
3. Patient Registration Committee, Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan (as of December 2002). Ther Apher Dial 2004 8 : 358 82.
4. Chertow BS, Baylink DJ, Wergedal JF et al. Decrease in serum immunoreactive parathyroid hormone in rats and in parathyroid hormone secretion in vitro by 1,25-dihydroxycholecalciferol. J Clin Invest 1975 56 : 668 78.
5. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984 74 : 2136 43.
6. 3 pulse therapy. Nephron 1989 51 : 130 1.
7. Fukuda N, Tanaka H, Tominaga Y et al. Decrease 1,25-dihydroxy-vitamin D3 receptor density is associated with a more severe from of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993 92 : 1436 43.
8. Fukagawa M, Kitaoka M, Yi H et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patient. Nephron 1994 68 : 221 8.
9. Tominaga Y, Kohara S, Namii Y et al. Clonally analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg 1996 20 : 744 50.
10. McCarron DA, Muther RS, Lenfesty B, Bennet WM. Parathyroid function in persistent hyperparathyroidism: relationship to gland size. Kidney Int 1982 22 : 662 70.
11. Lepage R, Louise R, Lean-Hugues B et al. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurement in uremic samples. Clin Chem 1998 44 : 805 9.
12. John MR, Goodman WG. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. JCEM 1999 84 : 4287 90.
13. Slatopolsky E, Finch J, Clay P, Martin D et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000 58 : 753 61.
14. Brossard J-H, Lepage R, Cardinal H et al. Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 2000 46 : 697 3.
15. Monier-Faugere M-C. Improved assessment of bone turnover by the PTH-(1-84) /large C-PTH fragment ratio in ESRD patients. Kidney Int 2001 60 : 1460 8.
16. Gao P. Development of a novel immunoradiometric assay exclusively for biological active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001 16 : 605 14.
17. Yamashita H, Gao P, Noguchi S et al. Role of cyclase activating parathyroid hormone (1-84 PTH) measurements during parathyroid surgery-Potential improvement of intraoperative PTH assay. Ann Surg 2002 236 : 105 11.
18. Silver J, Kilav R, Naveh-Many T. Mechanism of secondary hyperparathyroidism. Am J Physiol 2002 283 : F367 F76.
19. Slatopolsky E, Finch J, Denda M et al. Phosphorus restriction prevents secretion in vitro. J Clin Invest 1996 97 : 2534 40.
20. Inaba M, Okuno S, Chou H et al. Positive correlation of serum bio-intact PTH (1-84) but not intact PTH with parathyroid gland size in hemodialysis patients. Biopha 2006 60 : 62 5.
21. Tominaga Y, Numano M, Tanaka Y, Uchida K, Takagi H. Surgical indication and procedure of parathyroidectomy in patients with chronic kidney disease. Ther Apher Dial 2005 9 : 44 7.
22. Kakuta T, Fukagawa M, Fujisaki T et al. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping. Am J Kidney Dis 1999 33 : 1091 9.
23. Fukagawa M, Tominaga Y, Kitaoka M et al. Medical and surgical aspects of parathyroidectomy. Kidney Int 1999 56 : s-65 9.
24. Okuno S, Ishimura E, Kitatani K et al. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2003 18 : 2613 21.
25. Tominaga Y, Inaguma D, Matsuoka S et al. Is the Volume of the parathyroid gland a predictor of Maxacalcitol response in advanced secondary hyperparathyroidism? Ther Apher Dial 2006 10 : 198 4.
26. Tominaga Y, Matsuoka S, Sato T et al. Clinical features and Hyperplastic patterns of parathyroid glands in hemodialysis patients with advanced secondary hyperparathyroidism refractory to Maxacalcitol treatment and required parathyroidectomy. Ther Apher Dial 2007 11 : 266 73.